Quote:

---

A question regarding MANF IP expiration period of 7 years to which Dr. Rubinfeld mentioned that that would start the moment it was on the market. JC mentioned about a 12 year period.

---

In my communications with barcode27 following his return from the SHM, Gerald and Joe Rubenfeld discussed regulatory protections that essentially extend the patent protection. While it may take many years for a company to get their patented asset through trials and FDA approval, the regulatory protection gives exclusivity to the company for another 12 years once the asset reaches the commercial market. So even if the company has only a few years left on the patent protection, the company is assured of 12 years of exclusive sales once MANF is approved for use. This protection is for the USA, but similar protection is available for sales in Europe.

While I am not certain of this point, I would assume each different MANF treatment would have its own separate 12-year window, since one some cases MANF may be combined with other compounds or proteins, thereby differentiating it from previous MANF treatments.

Definitely good news for shareholders. This was something I had started thinking about over the last few months, but didn't mention it on the board, nor with the company. I feel even more confident since learning of the regulatory protection.
.